product
Eisai, Biogen report real-world Alzheimer's drug study results
Eisai and Biogen reported real-world study results for their Alzheimer's drug.
Markets open original ↗
Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Tue · 14 Jul
product
Eisai and Biogen reported real-world study results for their Alzheimer's drug.
Markets open original ↗
product
Eisai and Biogen reported new real-world study results for their Alzheimer's drug.
Markets open original ↗
product
Novo Nordisk reported positive new hemophilia trial results in both adults and children.
Markets open original ↗
funding
VERBUND joined ABB, Axpo, and DNV as a strategic investor in Gridcog's $10 million funding round.
Markets open original ↗
product
Biogen shares fell after disappointing trial data for its tau-targeting Alzheimer's drug.
Markets open original ↗